Everand Logo

Welcome to Everand!

  • STAT

    Plastic tubes can’t save the lives of liver failure patients, and a biotech’s stock price plummets

    Another effort by Vital Therapies to transform plastic tubes into a lifesaving artificial liver ended in disappointment.
    by Adam Feuerstein Sep 12, 2018 1 minute

    Another effort by Vital Therapies () to transform into a lifesaving artificial liver ended in disappointment Wednesday. And after this latest setback, the

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks